NovoCure's Phase 3 TRIDENT trial misses primary endpoint for earlier TTFields therapy
NovoCure announced topline results from its Phase 3 TRIDENT trial evaluating earlier initiation of Tumor Treating Fields therapy in newly diagnosed glioblastoma, which failed to meet its primary endpoint of demonstrating statistically significant overall survival improvement. The
View filing at SEC.gov →